Drug Profile
Research programme: TrkA receptor antagonists - Array BioPharma/Asahi Kasei Pharma
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Analgesics; Anti-inflammatories; Small molecules
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Pain in USA (PO)
- 28 Dec 2022 Discontinued for Inflammation in USA (PO)
- 28 Jun 2020 No recent reports of development identified for research development in Inflammation in USA (PO)